Amgen Inc. (AMGN), a biotechnology company based in Thousand Oaks, California, on Wednesday said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee unanimously voted to recommend approval of the romiplostim application. According to the company, the new application has the potential to be an important new treatment option for the orphan population of adult patients suffering from chronic immune thrombocytopenic purpura, an autoimmune disorder characterized by low platelet counts in the blood. The company believes that the data contained in its registrational clinical studies paired with the proposed comprehensive risk management program support approval by the FDA in the second quarter of this year.AMGN is currently trading at $45.38, up $0.76 or 1.70%, on 9.93 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.